TRIANNI Announces Issuance of Russian Federation Patent

"We are pleased with the addition of the Russian patent to our patent portfolio," commented Dr. Matthias Wabl, Ph.D., Chairman and CEO of TRIANNI. "This addition further strengthens TRIANNI's position in monoclonal antibody discovery platform."

SAN FRANCISCO, 02/03/2016 (informazione.it - comunicati stampa - scienza e tecnologia)

commented Dr. Matthias Wabl , Ph.D., Chairman and CEO of TRIANNI. "

Trianni is a privately held organization, formed in 2010 with a mission to use recent advances in DNA synthesis and genomic modification technology for the development of an optimized therapeutic antibody discovery platform, The Trianni Mouse. The company has research and administrative facilities in the San Francisco Bay Area (CA, USA) and in Research Triangle Park (NC, USA). For more information, please visit www.trianni.com.

Zishan Haroon , MD, PhD
Chief Business Officer
1.415.231.0257 [o]
drz@trianni.com

Mandy Boyd
Director of Marketing
1.415.231.0256 [o]
1.866.674.9314
mandy.boyd@trianni.com